Evidence map›Paper›PMID 39877440›Full record

ArticleDiabetology international2025

Practice guideline: Statement regarding treatment for suspected slowly progressive type 1 diabetes (SPIDDM; probable) cases (English Version).

Akira Shimada, Eiji Kawasaki, Norio Abiru, Takuya Awata, Yoichi Oikawa, Haruhiko Osawa, Hiroshi Kajio, Junji Kozawa, Kazuma Takahashi, Daisuke Chujo and 7 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetology international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Akira ShimadaDepartment of Endocrinology and Diabetes, Saitama Medical University, 38 Morohongo, Moroyama, Saitama, 350-0495 Japan.ORCID 0000-0002-3954-4983
Eiji KawasakiDiabetes Center, Shin-Koga Hospital, 120 Tenjin-Cho, Kurume-Shi, Fukuoka, 830-8577 Japan.
Norio AbiruMidori Clinic, 32-20 Joei-Machi, Nagasaki, 852-8034 Japan.
Takuya AwataDiabetes Research Center, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-Ku, Tokyo, 162-8655 Japan.
Yoichi OikawaDepartment of Endocrinology and Diabetes, Saitama Medical University, 38 Morohongo, Moroyama, Saitama, 350-0495 Japan.
Haruhiko OsawaDepartment of Diabetology, Ehime University Graduate School of Medicine, Toon, Shizugawa, Ehime 791-0295 Japan.
Hiroshi KajioDepartment of Diabetes, Endocrinology and Metabolism, National Center for Global Health and Medicine Hospital, 1-21-1 Toyama, Shinjuku-Ku, Tokyo 162-8655 Japan.
Junji KozawaEndowed Department of Diabetes Medicine, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871 Japan.
Kazuma TakahashiSchool of Nursing, Iwate Prefectural University, 152-52, Suuko, Takizawa, Iwate 020-0693 Japan.
Daisuke ChujoCenter for Clinical Research, Toyama University Hospital, 2630 Sugitani, Toyama, 930-0194 Japan.
Shinsuke NosoDepartment of Endocrinology, Metabolism and Diabetes, Faculty of Medicine, Kindai University, 377-2, Ohnohigashi, Osaka-Sayama, Osaka 589-8511 Japan.
Tomoyasu FukuiDivision of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, Showa University, 1-5-8 Hatanodai, Shinagawa-Ku, Tokyo 142-8555 Japan.
Junnosuke MiuraDivision of Diabetes and Metabolism, Department of Internal Medicine, Tokyo Women's Medical University School of Medicine, 8-1 Kawada-Cho, Shinjuku-Ku, Tokyo 162-8666 Japan.
Kazuki YasudaDepartment of Diabetes, Endocrinology and Metabolism, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka-Shi, Tokyo 181-8611 Japan.
Hisafumi YasudaDivision of Health Sciences, Department of Public Health, Kobe University Graduate School of Health Sciences, 7-10-2 Tomogaoka, Suma-Ku, Kobe, Hyogo 654-0142 Japan.
Akihisa ImagawaDepartment of Internal Medicine (I), Faculty of Medicine, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-Cho, Takatsuki, Osaka 569-8686 Japan.
Hiroshi IkegamiDepartment of Endocrinology, Metabolism and Diabetes, Faculty of Medicine, Kindai University, 377-2, Ohnohigashi, Osaka-Sayama, Osaka 589-8511 Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Insulin treatment should be introduced in patients with slowly progressive type 1 diabetes (SPIDDM; definite), according to the revised diagnostic criteria of SPIDDM (2023). In contrast, SPIDDM (probable) patients are in a non-insulin-dependent state; therefore, a more flexible treatment can be considered, although sulfonylurea agents should be avoided. Insulin treatment has been shown to maintain endogenous insulin secretion capacity in SPIDDM (probable); however, this does not mean that all SPIDDM (probable) patients should use insulin from the early phase. Dipeptidyl peptidase-4 inhibitors and biguanides might be the treatment of choice for SPIDDM (probable), but no evidence exists for other hypoglycemic agents. In any case, careful monitoring of the endogenous insulin secretion capacity should be carried out, and if a decrease in insulin secretion capacity is suspected, a change in treatment should be considered to prevent progression to an insulin-dependent state.

Indexed as

Hypoglycemic drugsInsulinInsulin-independent stateSlowly progressive insulin-dependent diabetesSlowly progressive type 1 diabetes

Identifiers

PMID39877440
PMCPMC11769915

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.